Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

New England Journal of Medicine

Volumn 346, Issue 2, 2002, Pages 92-98

  Schiller, Joan H ^a   Harrington, David ^b   Belani, Chandra P ^c   Langer, Corey ^d   Sandler, Alan ^e   Krook, James ^f   Zhu, Junming ^b   Johnson, David H ^g  

^a University of Wisconsin Health   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e INDIANA UNIVERSITY   (United States)

^f Duluth Clinic   (United States)

^g VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS;

EID: 0037050352     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa011954     Document Type: Article

References (21)

1. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - Report of a Canadian multicenter randomized trial
2. Chemotherapy vs. supportive care in advanced non-small-cell lung cancer: Results of a meta-analysis of the literature
3. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
4. Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough?
5. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life
6. A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small cell lung cancer (NSCLC)
7. A phase 2 study of gemcitabine with cisplatin in patients with non-small cell lung cancer
8. Cisplatin-gemcitabine combination in non-small cell lung cancer (NSCLC): A phase II study
9. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis
10. Phase II study of docetaxel (Taxotere) and cisplatin in advanced non small cell lung cancer (NSCLC): An interim analysis
11. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
12. Evaluation of survival data and two new rank order statistics arising in its consideration
13. A multiple testing procedure for clinical trials
14. Nonparametric estimation of incomplete observations
15. E1594 - A randomized phase III trial in metastatic non-small cell lung cancer (NSCLC) - Outcome of PS 2 patients (Pts): An Eastern Cooperative Oncology Group Trial (ECOG)
16. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group
17. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer
18. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer
19. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group
20. An economic analysis of Southwest Oncology Group Trial S9509: Cisplatin/vinorelbine vs. carboplatin/paclitaxel for advanced non-small cell lung cancer